Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.7180
-0.0280 (-3.75%)
Mar 31, 2025, 2:25 PM EDT - Market open
Xilio Therapeutics Employees
Xilio Therapeutics had 64 employees as of December 31, 2024. The number of employees decreased by 9 or -12.33% compared to the previous year.
Employees
64
Change (1Y)
-9
Growth (1Y)
-12.33%
Revenue / Employee
$99,125
Profits / Employee
-$910,016
Market Cap
37.17M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64 | -9 | -12.33% |
Dec 31, 2023 | 73 | -16 | -17.98% |
Dec 31, 2022 | 89 | 15 | 20.27% |
Dec 31, 2021 | 74 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
XLO News
- 20 days ago - Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 6 weeks ago - Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
- 6 weeks ago - Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewsWire
- 6 weeks ago - AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - GlobeNewsWire
- 2 months ago - Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire